IRWD Key Statistics, Chart & Performance
The current stock price of IRWD is 3.2 USD. In the past month the price decreased by -17.1%. In the past year, price decreased by -28.09%.
IRWD Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About IRWD
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Company Info
IRONWOOD PHARMACEUTICALS INC
100 Summer Street, Suite 2300
Boston MASSACHUSETTS 02110 US
CEO: Mark Mallon
Employees: 253
Phone: 16176217722
IRONWOOD PHARMACEUTICALS INC / IRWD FAQ
What does IRWD do?
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 253 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
What is the current price of IRWD stock?
The current stock price of IRWD is 3.2 USD. The price decreased by -1.84% in the last trading session.
What is the dividend status of IRONWOOD PHARMACEUTICALS INC?
IRWD does not pay a dividend.
What is the ChartMill technical and fundamental rating of IRWD stock?
IRWD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
On which exchange is IRWD stock listed?
IRWD stock is listed on the Nasdaq exchange.
Is IRONWOOD PHARMACEUTICALS INC (IRWD) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IRWD.
What is the expected growth for IRWD stock?
The Revenue of IRONWOOD PHARMACEUTICALS INC (IRWD) is expected to decline by -13.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
IRWD Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to IRWD. When comparing the yearly performance of all stocks, IRWD is one of the better performing stocks in the market, outperforming 93.42% of all stocks.
IRWD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IRWD. IRWD scores excellent on profitability, but there are concerns on its financial health.
IRWD Financial Highlights
Over the last trailing twelve months IRWD reported a non-GAAP Earnings per Share(EPS) of 0.26. The EPS increased by 2700% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.42% | ||
| ROA | 7.21% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IRWD Forecast & Estimates
9 analysts have analysed IRWD and the average price target is 2.55 USD. This implies a price decrease of -20.31% is expected in the next year compared to the current price of 3.2.
For the next year, analysts expect an EPS growth of 1404.5% and a revenue growth -13.42% for IRWD